Creativa Health
Menopause

HRT in 2026: What the Evidence Supports and What It Does Not

By Dr. Katherine Lewis, MD

If someone tells you HRT prevents heart disease or Alzheimer's, ask them which randomized trial showed that. The answer is: none.

If someone tells you HRT is dangerous and causes cancer, ask them whether they have read the WHI reanalysis data. The answer is usually no.

Hormone replacement therapy (HRT) is the most politically charged topic in women's health. The evidence supports a specific, nuanced position that is neither "miracle" nor "poison."

What Is Proven: Vasomotor Symptoms

HRT is the most effective treatment for hot flashes (75-95% reduction). 85% of menopausal women are affected. Symptoms persist a median of 7.4 years. The International Menopause Society, ACOG, and the Endocrine Society all endorse HRT as first-line for moderate-to-severe symptoms in women under 60 or within 10 years of menopause.

What Is Proven: Bone Protection

HRT reduces fracture risk by 30-40% during use. Licensed for osteoporosis prevention. Bone protection maintained only during use.

What the WHI Reanalysis Showed

Women Starting Within 10 Years of Menopause (Ages 50-59)

  • Breast cancer: No increased risk with estrogen-only (trend toward decreased). Estrogen-plus-progestin: modest increase (8 additional cases per 10,000 women-years).
  • Cardiovascular disease: No increased risk.
  • Overall mortality: 18-year follow-up showed no increase in all-cause mortality.
  • Colon cancer, diabetes, fractures: All decreased.

Women Starting 10+ Years After Menopause (Ages 70-79)

  • Cardiovascular and dementia risk increased.
  • WHIMS doubled dementia risk in women 65-79.

The WHI enrolled women averaging age 63. Applying those results to 50-year-old women was scientifically inappropriate.

FDA and the Black Box

The FDA removed the black box warning from MHT in 2025, reflecting updated evidence.

What Is NOT Proven: Cardiovascular Prevention

No RCT has proven HRT prevents heart disease. The "timing hypothesis" is biologically plausible but unproven. The ELITE and KEEPS trials tested surrogate endpoints only.

What Is NOT Proven: Alzheimer's Prevention

Observational data suggest protection with early HRT. Randomized trials have not confirmed it. Healthy-user bias is the most likely explanation for the observational findings.

Transdermal vs. Oral

Transdermal estrogen (patches, gels) bypasses the liver: no increased VTE risk, no triglyceride elevation, no increased stroke risk. Multiple studies confirm a safer profile than oral. Transdermal is preferred for most women.

The Progestogen Question

  • Micronized progesterone (Prometrium): Best safety profile, beneficial for sleep.
  • MPA (used in WHI): Associated with breast cancer risk increase.
  • Levonorgestrel IUD (Mirena): Local endometrial protection, minimal systemic exposure.

Premature Ovarian Insufficiency

Women with menopause before 40 need 3-4x standard doses. HRT strongly recommended until at least age 51-52.

Contraindications

  • Active or recent breast cancer
  • Active liver disease
  • Unexplained vaginal bleeding
  • Known thrombophilia with personal VTE history
  • Active cardiovascular disease

The Honest Position

HRT is the most effective treatment for vasomotor symptoms and a proven bone tool. For women under 60 starting within 10 years of menopause, the evidence supports favorable benefit-risk. Transdermal estrogen with micronized progesterone has the best safety profile. But HRT is not a longevity drug, not a proven cardiovascular protectant, and not a cognitive enhancement tool.

FAQ

Q: Does HRT cause breast cancer?
A: Estrogen-only did not increase risk in WHI (trend toward decrease). Estrogen plus synthetic progestin (MPA) showed a modest increase. Micronized progesterone appears safer than MPA.

Q: Is it too late to start HRT after age 60?
A: Starting 10+ years after menopause carries higher cardiovascular and cognitive risks. The best benefit-risk is within 10 years of menopause.

Q: Does HRT prevent heart disease?
A: No RCT has proven this. The timing hypothesis is plausible but unproven. Do not start HRT solely for cardiovascular protection.

Q: Are patches safer than pills for HRT?
A: Yes. Transdermal estrogen has no increased VTE risk, no triglyceride elevation, no increased stroke risk at standard doses.

Q: How long can you stay on HRT?
A: No mandatory stop date. Annual reassessment. Many women continue for years or decades when benefits persist and profile remains favorable.

Sources

  1. Rossouw JE et al. - WHI: Estrogen Plus Progestin - PubMed
  2. Manson JE et al. - WHI 18-Year Mortality Follow-Up - PubMed
  3. Shumaker SA et al. - WHIMS - PubMed
  4. Hodis HN et al. - ELITE Trial - PubMed
  5. Harman SM et al. - KEEPS Trial - PubMed
  6. Canonico M et al. - Oral vs Transdermal VTE Risk - PubMed
  7. Fournier A et al. - Breast Cancer by HRT Type (E3N) - PubMed
  8. Avis NE et al. - Vasomotor Symptoms (SWAN) - PubMed
  9. Baber RJ et al. - IMS Recommendations - PubMed
  10. The Menopause Society - Hormone Therapy Position (2022)
  11. ACOG - Hormone Therapy in POI
  12. FDA - Black Box Removal from MHT (2025)
  13. LaCroix AZ et al. - Outcomes After Stopping CEE (WHI) - PubMed
  14. Anderson GL et al. - CEE in Women with Hysterectomy (WHI) - PubMed
  15. Lobo RA - HRT: Current Thinking - PubMed
  16. Stuenkel CA et al. - Endocrine Society Guideline on Menopause - PubMed

This content is for informational purposes only and does not constitute medical advice. Consult your physician before starting any supplement or making changes to your health regimen.